Abstract
Recent research evidence documents that lncRNAs (long non-coding RNAs lncRNAs) play a pivotal role in the tumorigenesis and development of tumors. LncRNA SNGH3 (small nucleolar RNA host gene 3) is highly expressed in numerous forms of cancer, serving as an oncogene in cancer progression. Nonetheless, the clinical relationship, along with the mechanism of SNGH3 in bladder cancer, have not been studied. Herein, the findings exhibited upregulation of SNGH3 in bladder cancer tissues, along with the cell lines. Furthermore, overexpressed SNGH3 was positively linked to the TNM stage, as well as the histological grade of bladder cancer. Moreover, the silencing of SNGH3, using CRISPR-dCas9, suppressed cell growth along with migration, but elevated bladder cancer cell apoptosis. In summary, we established that SNGH3 serves as a bladder cancer oncogene and could be employed as a prospective diagnostic marker for clinical use, and is also a therapeutic target for CRISPR-mediated gene therapy.
Highlights
Human bladder cancer, which has high incidence and a high mortality, is the most frequent type of the urinary system tumors
Mounting research evidence suggest that Long non-coding RNA (lncRNA) are involved with gene expression regulation by affecting the gene transcription, post-transcriptional process, and chromatin modification (Meller et al, 2015; Engreitz et al, 2016)
LncRNAs participate in modulatory roles in most the biological processes, constituting cell growth, tissue, as well as organ development, cell apoptosis, energy metabolism, and so on (Kopp and Mendell, 2018; Krause, 2018)
Summary
Human bladder cancer, which has high incidence and a high mortality, is the most frequent type of the urinary system tumors. There are approximately 549,000 new cases of bladder cancer and 200,000 people died of the disease in 2018 (Bray et al, 2018). Diagnosis and treatment of bladder cancer is strongly linked to the prognosis of patients. Frequent relapse along with distant metastasis of bladder cancer are the primary causes of treatment failure. The exact molecular biology of bladder cancer remains unknown. It is critical to find new effective biological targets for the diagnosis, as well as the treatment of bladder cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.